| pubmed-article:21420732 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21420732 | lifeskim:mentions | umls-concept:C1518578 | lld:lifeskim |
| pubmed-article:21420732 | lifeskim:mentions | umls-concept:C0026986 | lld:lifeskim |
| pubmed-article:21420732 | lifeskim:mentions | umls-concept:C0004475 | lld:lifeskim |
| pubmed-article:21420732 | lifeskim:mentions | umls-concept:C0332161 | lld:lifeskim |
| pubmed-article:21420732 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:21420732 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:21420732 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:21420732 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:21420732 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:21420732 | lifeskim:mentions | umls-concept:C0556987 | lld:lifeskim |
| pubmed-article:21420732 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:21420732 | pubmed:dateCreated | 2011-7-18 | lld:pubmed |
| pubmed-article:21420732 | pubmed:abstractText | Prolonged administration of methyl transferase inhibitors may increase response rates in myelodysplastic syndromes (MDS). Fourteen MDS patients with anemia and less than 10% marrow blasts received azacitidine 50 mg/m(2) thrice weekly for 2 weeks every 4 weeks; 7 also received weekly erythropoietin. The response rate of 43% did not improve the rates reported with other azacitidine administration schedules, so the study was closed. A decreased apoptosis of primitive erythroid progenitors and increased expression of BclX(L) was observed with treatment in responding patients compared to non-responders. Azacitidine may modulate BclX(L) and improve erythropoiesis through reduction of apoptosis in primitive erythroid progenitor population in MDS. | lld:pubmed |
| pubmed-article:21420732 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21420732 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21420732 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21420732 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21420732 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21420732 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21420732 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21420732 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21420732 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21420732 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:21420732 | pubmed:issn | 1873-5835 | lld:pubmed |
| pubmed-article:21420732 | pubmed:author | pubmed-author:CripeLarry... | lld:pubmed |
| pubmed-article:21420732 | pubmed:author | pubmed-author:ChanRebecca... | lld:pubmed |
| pubmed-article:21420732 | pubmed:author | pubmed-author:OrschellChris... | lld:pubmed |
| pubmed-article:21420732 | pubmed:author | pubmed-author:SayarHamidH | lld:pubmed |
| pubmed-article:21420732 | pubmed:author | pubmed-author:WuJingweiJ | lld:pubmed |
| pubmed-article:21420732 | pubmed:author | pubmed-author:ChanEdward... | lld:pubmed |
| pubmed-article:21420732 | pubmed:author | pubmed-author:YangZhenyunZ | lld:pubmed |
| pubmed-article:21420732 | pubmed:author | pubmed-author:WalterAmandaA | lld:pubmed |
| pubmed-article:21420732 | pubmed:author | pubmed-author:YuZhangshengZ | lld:pubmed |
| pubmed-article:21420732 | pubmed:author | pubmed-author:HoodDanielD | lld:pubmed |
| pubmed-article:21420732 | pubmed:author | pubmed-author:NabingerSarah... | lld:pubmed |
| pubmed-article:21420732 | pubmed:author | pubmed-author:PlettArturA | lld:pubmed |
| pubmed-article:21420732 | pubmed:author | pubmed-author:HuiChua LinCL | lld:pubmed |
| pubmed-article:21420732 | pubmed:author | pubmed-author:KohlbacherKri... | lld:pubmed |
| pubmed-article:21420732 | pubmed:author | pubmed-author:WestEvan SES | lld:pubmed |
| pubmed-article:21420732 | pubmed:author | pubmed-author:SampsonCarolC | lld:pubmed |
| pubmed-article:21420732 | pubmed:copyrightInfo | Copyright © 2011 Elsevier Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:21420732 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21420732 | pubmed:volume | 35 | lld:pubmed |
| pubmed-article:21420732 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21420732 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21420732 | pubmed:pagination | 1108-10 | lld:pubmed |
| pubmed-article:21420732 | pubmed:meshHeading | pubmed-meshheading:21420732... | lld:pubmed |
| pubmed-article:21420732 | pubmed:meshHeading | pubmed-meshheading:21420732... | lld:pubmed |
| pubmed-article:21420732 | pubmed:meshHeading | pubmed-meshheading:21420732... | lld:pubmed |
| pubmed-article:21420732 | pubmed:meshHeading | pubmed-meshheading:21420732... | lld:pubmed |
| pubmed-article:21420732 | pubmed:meshHeading | pubmed-meshheading:21420732... | lld:pubmed |
| pubmed-article:21420732 | pubmed:meshHeading | pubmed-meshheading:21420732... | lld:pubmed |
| pubmed-article:21420732 | pubmed:meshHeading | pubmed-meshheading:21420732... | lld:pubmed |
| pubmed-article:21420732 | pubmed:meshHeading | pubmed-meshheading:21420732... | lld:pubmed |
| pubmed-article:21420732 | pubmed:meshHeading | pubmed-meshheading:21420732... | lld:pubmed |
| pubmed-article:21420732 | pubmed:meshHeading | pubmed-meshheading:21420732... | lld:pubmed |
| pubmed-article:21420732 | pubmed:meshHeading | pubmed-meshheading:21420732... | lld:pubmed |
| pubmed-article:21420732 | pubmed:meshHeading | pubmed-meshheading:21420732... | lld:pubmed |
| pubmed-article:21420732 | pubmed:meshHeading | pubmed-meshheading:21420732... | lld:pubmed |
| pubmed-article:21420732 | pubmed:meshHeading | pubmed-meshheading:21420732... | lld:pubmed |
| pubmed-article:21420732 | pubmed:meshHeading | pubmed-meshheading:21420732... | lld:pubmed |
| pubmed-article:21420732 | pubmed:meshHeading | pubmed-meshheading:21420732... | lld:pubmed |
| pubmed-article:21420732 | pubmed:meshHeading | pubmed-meshheading:21420732... | lld:pubmed |
| pubmed-article:21420732 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21420732 | pubmed:articleTitle | Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: a study of the Hoosier Oncology Group. | lld:pubmed |
| pubmed-article:21420732 | pubmed:affiliation | Division of Hematology and Oncology, Department of Medicine, Indiana University Simon Cancer Center, Indianapolis, IN 46202, USA. ssayar@iupui.edu | lld:pubmed |
| pubmed-article:21420732 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21420732 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:21420732 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
